新泽西经济发展局批准约6000万美元税收抵免 支持安姆尼尔在皮斯卡特韦扩产
新泽西州米德尔塞克斯县皮斯卡特韦市消息，新泽西州经济发展局董事会10月26日批准，根据“下一代新泽西制造业计划”向安姆尼尔制药公司提供约6000万美元税收抵免，支持其在皮斯卡特韦的制造扩张。安姆尼尔总部位于布里奇沃特，由兄弟奇拉格·帕特尔与钦图·帕特尔于2002年在帕特森创立，是一家专注开发、制造、商业化与分销平价创新药物的全球生物制药公司。该项目三年内合格资本投资超过2.4亿美元，预计创造330多个全职工作岗位，进一步巩固新泽西州在全国制药制造领域的地位。扩张旨在支持安姆尼尔平价药物业务的持续增长，包括复杂仿制药、女性健康产品与新产品上市，以及生物类似药产品组合的推进，项目还包括扩大透皮贴剂、生物类似药与药品注射剂的制造能力。安姆尼尔拥有300多种仿制药、专科药与生物类似药，每年交付处方超过1.6亿张。
NJEDA approves about $60 million in tax credits to support Amneal expansion in Piscataway
Piscataway, Middlesex County, New Jersey — The New Jersey Economic Development Authority's board approved on Oct. 26 the award of about $60 million in tax credits under the Next New Jersey Manufacturing Program to Amneal Pharmaceuticals to support its manufacturing expansion in Piscataway. Amneal is headquartered in Bridgewater and was founded in Paterson in 2002 by brothers Chirag Patel and Chintu Patel; it is a global biopharmaceutical company focused on developing, manufacturing, commercializing and distributing affordable innovative medicines. The project involves more than $240 million in qualified capital investment over three years and is expected to create more than 330 full-time jobs, further consolidating New Jersey's position in pharmaceutical manufacturing nationwide. The expansion aims to support continued growth of Amneal's affordable-medicines business, including complex generics, women's health products and new product launches, as well as advancement of its biosimilars portfolio, and includes expanded manufacturing capacity for transdermal patches, biosimilars and injectable drugs. Amneal has more than 300 generic, specialty and biosimilar products and delivers more than 160 million prescriptions a year.
来源：GSM·美国（原文链接）
图片来源：新泽西州议会大厦，CC BY-SA 4.0，来源 Wikimedia Commons
